Vuori Kristiina MD's Form 4/A amendment
AmendedInhibrx Biosciences, Inc. (INBX) · filed Sep 18, 2026
- Accession no.
- 0001612627-26-000007
- Filed
- Sep 18, 2026, 4:25 PM ET
- Trade date
- Jun 3, 2026
- Filing delay
- 107 days
- Rule 10b5-1 plan
- Not checked
- Original filed
- Jun 4, 2026
This filing lists 1 derivative transaction. It was filed 107 days after the trade.
This amendment replaces 0001612627-26-000004 (filed Jun 4, 2026).
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Vuori Kristiina MDCIK 0001612627 | Director |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
This filing has no transactions of this kind.
Derivative securities (Table II)
Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.
| Trade date | Security | Transaction | Underlying shares | Unit price | Value | Held after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Jun 3, 2026 | Common Stock | AGrant or awardAcquired | +10,000 | $0.00 | $0 | 10,000 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
This stock option will be fully exercisable on June 3, 2027, subject to the reporting person's continued service through such date.
Remarks
This Amended Form 4 restates the original Form 4 filed on June 4, 2026 in its entirety to correct the number of options granted to the Reporting Person due to an administrative error.